Back to Insights

China’s NRDL 2022 Update: Spotlight on Rare Disease (Part 3 of 3)

With negotiated prices as much as 95% below launch pricing, marketing rare disease therapies in China is a challenge. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan discuss alternate access channels. Download the free brief (part 3 of 3).

DOWNLOAD THE BRIEF HERE!